Quest Diagnostics announced that it has completed its acquisition of PathAI Diagnostics, PathAI's anatomic and digital pathology lab services business.
The acquisition of PathAI's lab assets was initiated and announced in early May.
Under the terms of the acquisition, the PathAI Diagnostics digitized laboratory in Memphis has been rebranded as AmeriPath and will act as the national artificial intelligence (AI) and digital R&D and solutions center for Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics.
PathAI, which remains an independent company, will maintain a separate research lab at the same site in Memphis to support its biopharmaceutical clients, according to a statement from the companies.
Additionally, PathAI and Quest have forged agreements to further advance the adoption of AI and digital pathology. Specifically, Quest will license PathAI's AISight digital pathology image management system for its U.S. pathology labs and customer sites. In turn, Quest is a preferred lab services partner for PathAI's biopharmaceutical clients. PathAI and Quest may collaborate on developing AI algorithms for research and clinical applications, the firms added.
